Friday, 21 Sep 2018

You are here

BMS Tyk 2 Inhibitor Benefits Psoriasis

The NEJM reports that an oral selecive Tyrosine kinase 2 (TYK2) inhibitor of TYK2 was shown to be superior to placebo in a 12 week trial in patients with active psoriasis.

In a 12 week, phase 2, double-blind trial, BMS-986165 (TYK2 inhibitor) or placebo was given to 267 patients with active moderate-to-severe psoriasis, who previously failed to respond to other targeted cytokine inhibitors.  Patients received wither 3 mg every other day, 3 mg daily, 3 mg twice daily, 6 mg twice daily, or 12 mg daily or to receive placebo. The primary end point was a 75% or greater reduction from baseline in the Psoriasis Area and Severity Index (PASI75) score at week 12.

At week 12, the PASI 75 response rates were:

  • PBO: 7% (3 of 45 patients)
  • 3 mg of BMS-986165 qod;  9% (4 of 44 patients) (P=0.49 vs. placebo)
  • 3 mg qd: 39% (17 of 44 patients) (P<0.001 vs. placebo)
  • 3 mg bid:  69% (31 of 45 patients) (P<0.001 vs. placebo)
  • 6 mg bid: 67% (30 of 45 patients) (P<0.001 vs. placebo)
  • 12 mg qd: 75% (33 of 44 patients) (P<0.001 vs. placebo).

Discontinuation rates were low, generally about 2% (ranging from 2-7%) and there were 3 serious adverse events in patients receiving the active drug, as well as one case of malignant melanoma 96 days after the start of treatment.

Targeted inhibition of TYK2 with the oral agent BMS-986165 at doses of 3 mg daily and higher resulted in significant clearing of psoriasis.

(Funded by Bristol-Myers Squibb; number, NCT02931838.)

The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Biologic Therapies Improve Work Outcomes in Spondyloarthritis

A study from the British Society for Rheumatology Biologics Register in Axial Spondyloarthritis (BSRBR-AS) shows that biologic use significantly improves work productivity and overall activity impairment.


The BSRBR-AS registry analyzed 577 participants who were employed;  28% were started on biological therapy .

Methotrexate's Low Efficacy in Cutaneous Psoriasis

In a prospective, double-blind, randomized placebo-controlled study, Warren et al. studied the effect of an intensified methotrexate (MTX) in chronic plaque psoriasis and showed MTX to be effective and superior to placebo.

No Cancer Risk from Psoriatic Arthritis

Inflammmation is a strong risk factor for malignancy. Yet there are mixed results on whether patients with psoriatic arthritis (PsAg) augments the incidence of cancer and all-cause and cause-mortality.

A study from the national British Society for Rheumatology Biologics Register examined the risk of cancer, assessed by standardized incidence ratios (SIRs)  or standardized mortality ratios (SMRs).

Treatments Do Not Increase Infection Risk in Ankylosing Spondylitis

A large Canadian study of the drug use in ankylosing spondylitis (AS) demonstrated no evidence that the risk of serious,  hospitalized infection was influenced by the use of DMARD and/or of tumour necrosis factor inhibitors (TNFi) therapy.

They studied 747 AS patients who initiated TNFI and/or DMARDs between 2001 and 2011 to identify hospitalized infection  coding data and hospital discharge diagnoses.

Dietary Recommendations for Psoriatic Disease

A systematic review by the Medical Board of the National Psoriasis Foundation examined the role of diet in managing adult patients with psoriasis and/or psoriatic arthritis and suggest that dietary interventions to reduce disease severity.

A metanalysis of 55 studies and 4534 patients with psoriasis examined the role of weight loss, gluten-free diets, vitamin supplementation on reducing psoriatic disease activity.